YUBIOLOGICS, 20.26% ↑ on COVID-19 (Diagnosis/Treatment/Vaccine Development) Theme Uptrend
On the 4th, the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme rose by 3.16% compared to the previous day, showing strength, while YuvioLogics, a related stock drawing attention, surged by 20.26% compared to the previous day. YuvioLogics is known as a research and development company of biological preparations and pharmaceuticals.
[Graph] Major stock price changes in the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme
According to the analysis by Thinkpool RoboAlgorithm RASSI, YuvioLogics’ quant financial score is 44.46 points, which is higher in growth and profitability scores than the average of other stocks related to the COVID-19 (diagnosis/treatment/vaccine development, etc.) theme, ranking 11th within the theme. This indicates that compared to other stocks in the theme, YuvioLogics has a relatively fast increase in sales and net profit, and also shows good efficient profit-generating ability.
[Table] Top financial scores within the theme
※ The quant financial score is the result of RoboAlgorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.
※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- [PE Now] F&B Companies Making a Second Attempt at Sale: The Formula for a Successful Deal
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.